Menachem Gross1,2,3, Fadi Ashqar4, Ronit Vogt Sionov5, Michael Friedman6,7, Ron Eliashar4,6, Batya Zaks5, Irith Gati7, Danielle Duanis-Assaf5, Mark Feldman5, Doron Steinberg5. 1. Department of Otolaryngology - Head and Neck Surgery, Hadassah Hebrew University Medical Center, P.O.Box 12000, 91120, Jerusalem, Israel. drgrossm@hotmail.com. 2. Biofilm Research Laboratory, Institute of Dental Sciences, Hebrew University, 91120, Jerusalem, Israel. drgrossm@hotmail.com. 3. School of Medicine, Hebrew University, Jerusalem, Israel. drgrossm@hotmail.com. 4. Department of Otolaryngology - Head and Neck Surgery, Hadassah Hebrew University Medical Center, P.O.Box 12000, 91120, Jerusalem, Israel. 5. Biofilm Research Laboratory, Institute of Dental Sciences, Hebrew University, 91120, Jerusalem, Israel. 6. School of Medicine, Hebrew University, Jerusalem, Israel. 7. School of Pharmacy, Hebrew University, Jerusalem, Israel.
Abstract
OBJECTIVES: In this study, we aimed to develop a novel, sustained release varnish (SRV) for voice prostheses (VP) releasing chlorhexidine (CHX), for the prevention of biofilm formation caused by the common oral bacteria Streptococcus mutans on VP surfaces. METHODS: This study was performed in an in vitro model as a step towards future in vivo trials. VPs were coated with a SRV containing CHX (SRV-CHX) or SRV alone (placebo-SRV) that were daily exposed to S. mutans. The polymeric materials of SRV were composed of ethylcellulose and PEG-400. Biofilm formation was assessed by DNA quantification (qPCR), crystal violet staining, confocal laser scanning microscopy (CLSM), scanning electron microscopy (SEM), and kinetics experiments. RESULTS: The amount of DNA in the biofilms formed by S. mutans on VP surfaces coated once with SRV-CHX (1.024 ± 0.218 ng DNA/piece) was 58.5 ± 8.8% lower than that of placebo-SRV-coated VPs (2.465 ± 0.198 ng DNA/piece) after a 48-h exposure to S. mutans (p = 0.038). Reduced biofilm mass on SRV-CHX-coated VPs was visually confirmed by CLSM and SEM. CV staining of SRV-CHX single-coated VPs that have been exposed to S. mutans nine times showed a 98.1 ± 0.2% reduction in biofilm mass compared to placebo-SRV-coated VPs (p = 0.003). Kinetic experiments revealed that SRV-CHX triple-coated VPs could delay bacterial growth for 23 days. CONCLUSIONS: Coating VPs with SRV-CHX has an inhibitory effect on biofilm formation and prevents bacterial growth in their vicinities. This study is a proof-of-principle that paves the way for developing new clinical means for reducing both VPs' bacterial biofilm formation and device failure.
OBJECTIVES: In this study, we aimed to develop a novel, sustained release varnish (SRV) for voice prostheses (VP) releasing chlorhexidine (CHX), for the prevention of biofilm formation caused by the common oral bacteria Streptococcus mutans on VP surfaces. METHODS: This study was performed in an in vitro model as a step towards future in vivo trials. VPs were coated with a SRV containing CHX (SRV-CHX) or SRV alone (placebo-SRV) that were daily exposed to S. mutans. The polymeric materials of SRV were composed of ethylcellulose and PEG-400. Biofilm formation was assessed by DNA quantification (qPCR), crystal violet staining, confocal laser scanning microscopy (CLSM), scanning electron microscopy (SEM), and kinetics experiments. RESULTS: The amount of DNA in the biofilms formed by S. mutans on VP surfaces coated once with SRV-CHX (1.024 ± 0.218 ng DNA/piece) was 58.5 ± 8.8% lower than that of placebo-SRV-coated VPs (2.465 ± 0.198 ng DNA/piece) after a 48-h exposure to S. mutans (p = 0.038). Reduced biofilm mass on SRV-CHX-coated VPs was visually confirmed by CLSM and SEM. CV staining of SRV-CHX single-coated VPs that have been exposed to S. mutans nine times showed a 98.1 ± 0.2% reduction in biofilm mass compared to placebo-SRV-coated VPs (p = 0.003). Kinetic experiments revealed that SRV-CHX triple-coated VPs could delay bacterial growth for 23 days. CONCLUSIONS: Coating VPs with SRV-CHX has an inhibitory effect on biofilm formation and prevents bacterial growth in their vicinities. This study is a proof-of-principle that paves the way for developing new clinical means for reducing both VPs' bacterial biofilm formation and device failure.
Authors: Kevin J D A Buijssen; Bernard F A M van der Laan; Henny C van der Mei; Jelly Atema-Smit; Pauline van den Huijssen; Henk J Busscher; Hermie J M Harmsen Journal: Head Neck Date: 2011-09-22 Impact factor: 3.147
Authors: E P Everaert; H F Mahieu; B van de Belt-Gritter; A J Peeters; G J Verkerke; H C van der Mei; H J Busscher Journal: Arch Otolaryngol Head Neck Surg Date: 1999-12
Authors: M G Bueno; V M Urban; G S Barbério; W J da Silva; V C Porto; LdeR Pinto; K H Neppelenbroek Journal: Oral Dis Date: 2013-12-10 Impact factor: 3.511
Authors: E P Everaert; B van de Belt-Gritter; H C van der Mei; H J Busscher; G J Verkerke; F Dijk; H F Mahieu; A Reitsma Journal: J Mater Sci Mater Med Date: 1998-03 Impact factor: 3.896
Authors: Dragana Ajdić; William M McShan; Robert E McLaughlin; Gorana Savić; Jin Chang; Matthew B Carson; Charles Primeaux; Runying Tian; Steve Kenton; Honggui Jia; Shaoping Lin; Yudong Qian; Shuling Li; Hua Zhu; Fares Najar; Hongshing Lai; Jim White; Bruce A Roe; Joseph J Ferretti Journal: Proc Natl Acad Sci U S A Date: 2002-10-23 Impact factor: 11.205